IO-125, a novel supramolecular platinum chemotherapy, is being developed in Triple-Negative Breast Cancer (TNBC)
Invictus Oncology, a leader in supramolecular therapeutics in oncology, will present pre-clinical results of their lead molecule, IO-125, at ASCO 2015 Breast Cancer Symposium, which will be held in San Francisco, CA. IO-125 is a novel platinum-based supramolecular therapeutic and is being developed in triple-negative breast cancer. The results will be shared at the poster presentation on September 26. It can also be viewed on the ASCO website, www.asco.org [http://www.asco.org ].
TNBC accounts for 15-20 per cent of all breast cancers and is associated with a poor prognosis, with a median survival of 13 months. There are limited treatment options for this disease. Recent studies have indicated clinical benefits of platinum agents in TNBC.
Scientists at Invictus Oncology designed IO-125 for superior anti-tumour activity by discovering a novel highly active platinum agent and then utilised their supramolecular platform to enhance its biodistribution to tumours vs. normal tissues. The results show that IO-125 has remarkable and sustained activity in TNBC xenograft models. Based on these observations, IO-125 has entered late stages of pre-clinical development.